$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023084520 Filed on November 08, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$450.0K	$453.7K	$217.9K
YoY Change	106.48%	30.69%
Cost Of Revenue	$65.49K	$79.75K	$60.82K
YoY Change	7.68%	22.65%
Gross Profit	$384.5K	$374.0K	$157.1K
YoY Change	144.73%	32.55%
Gross Profit Margin	85.45%	82.42%	72.09%
Selling, General & Admin	$2.503M	$1.720M	-$149.3K
YoY Change	-1777.23%	-35.13%
% of Gross Profit	651.01%	459.93%	-94.99%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$7.240K	$7.774K	$149.1K
YoY Change	-95.14%	-498.67%
% of Gross Profit	1.88%	2.08%	94.88%
Operating Expenses	$2.504M	$1.720M	-$149.3K
YoY Change	-1777.39%	-35.12%
Operating Profit	-$2.119M	-$1.346M	$306.4K
YoY Change	-791.64%	-43.18%
Interest Expense	-$246.7K	$144.5K	-$126.3K
YoY Change	95.31%	38.55%
% of Operating Profit			-41.23%
Other Income/Expense, Net	-$291.3K	-$431.8K	-$291.3K
YoY Change	0.0%	-40.11%
Pretax Income	-$3.511M	-$1.778M	-$193.2K
YoY Change	1717.23%	-42.46%
Income Tax	$10.00		$7.680K
% Of Pretax Income
Net Earnings	-$3.510M	-$1.778M	-$200.6K
YoY Change	1649.52%	-42.46%
Net Earnings / Revenue	-779.96%	-391.9%	-92.05%
Basic Earnings Per Share		-$0.04
Diluted Earnings Per Share	-$0.09	-$0.04	-$0.01
COMMON SHARES
Basic Shares Outstanding	39.97M shares	39.97M shares	40.29M shares
Diluted Shares Outstanding		39.97M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.9K	$340.0K	$1.000M
YoY Change	-86.61%	-68.45%
Cash & Equivalents	$100.3K	$200.4K	$751.0K
Short-Term Investments	$33.59K	$130.0K	$249.1K
Other Short-Term Assets
YoY Change
Inventory		$6.979K
Prepaid Expenses
Receivables	$572.7K	$570.0K	$525.1K
Other Receivables	$100.0K	$200.0K	$200.7K
Total Short-Term Assets	$806.6K	$1.114M	$1.726M
YoY Change	-53.26%	-33.72%	-16.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.16K	$80.35K	$56.20K
YoY Change	-30.31%	165.01%	1144.38%
Goodwill		$815.5K	$815.5K
YoY Change		-77.57%	-71.09%
Intangibles	$0.00	$2.000K	$2.750K
YoY Change	-100.0%	-99.88%	-99.86%
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$263.5K	$1.236M	$1.214M
YoY Change	-78.3%	-78.42%	-78.74%
TOTAL ASSETS
Total Short-Term Assets	$806.6K	$1.114M	$1.726M
Total Long-Term Assets	$263.5K	$1.236M	$1.214M
Total Assets	$1.070M	$2.350M	$2.940M
YoY Change	-63.6%	-68.27%	-62.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.154M	$1.080M	$738.4K
YoY Change	56.33%	-31.95%	-13.26%
Accrued Expenses	$1.043M	$667.4K	$581.8K
YoY Change	79.32%	923.33%	44.83%
Deferred Revenue
YoY Change
Short-Term Debt	$1.856M	$1.790M	$140.3K
YoY Change	1223.07%	1155.0%
Long-Term Debt Due	$3.921M	$3.630M	$5.300K
YoY Change	73881.89%	68390.57%
Total Short-Term Liabilities	$8.034M	$7.258M	$1.533M
YoY Change	424.14%	303.04%	8.18%
LONG-TERM LIABILITIES
Long-Term Debt	$1.590K	$0.00	$2.767M
YoY Change	-99.94%	-100.0%
Other Long-Term Liabilities	$1.592K	$2.839K	$283.1K
YoY Change	-99.44%	-99.06%
Total Long-Term Liabilities	$1.592K	$2.839K	$3.050M
YoY Change	-99.95%	-99.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.034M	$7.258M	$1.533M
Total Long-Term Liabilities	$1.592K	$2.839K	$3.050M
Total Liabilities	$8.211M	$7.513M	$4.582M
YoY Change	79.19%	64.11%	93.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.13M	-$26.62M	-$19.03M
YoY Change	58.33%	41.38%	129.1%
Common Stock	$39.97K	$39.97K	$38.29K
YoY Change	4.39%	-0.79%	45.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.138M	-$5.161M	-$1.641M
YoY Change
Total Liabilities & Shareholders Equity	$1.070M	$2.350M	$2.940M
YoY Change	-63.6%	-68.27%	-62.23%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.510M	-$1.778M	-$200.6K
YoY Change	1649.52%	-42.46%
Depreciation, Depletion And Amortization	$7.240K	$7.774K	$149.1K
YoY Change	-95.14%	-498.67%
Cash From Operating Activities	-$516.7K	-$880.0K	-$1.005M
YoY Change	-48.58%	-0.01%
INVESTING ACTIVITIES
Capital Expenditures	-$4.570K	$20.00K	$28.16K
YoY Change	-116.23%	-191.41%
Acquisitions
YoY Change
Other Investing Activities	$2.710K	$0.00	-$100.0K
YoY Change	-102.71%
Cash From Investing Activities	-$2.720K	-$10.00K	-$128.2K
YoY Change	-97.88%	-54.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	418.7K	900.0K	1.203M
YoY Change	-65.2%	142.48%
NET CHANGE
Cash From Operating Activities	-516.7K	-880.0K	-1.005M
Cash From Investing Activities	-2.720K	-10.00K	-128.2K
Cash From Financing Activities	418.7K	900.0K	1.203M
Net Change In Cash	-100.7K	10.00K	70.14K
YoY Change	-243.56%	-101.88%
FREE CASH FLOW
Cash From Operating Activities	-$516.7K	-$880.0K	-$1.005M
Capital Expenditures	-$4.570K	$20.00K	$28.16K
Free Cash Flow	-$512.1K	-$900.0K	-$1.033M
YoY Change	-50.42%	4.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y3M
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment		usd
CY2022	ohcs	Coupon Percentage CouponPercentage		pure
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	570466	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	525064	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	6979	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	201333	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-261849
	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
	dei	City Area Code CityAreaCode	(516)
	dei	Local Phone Number LocalPhoneNumber	806-4201
	dei	Security12b Title Security12bTitle	None
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39967598	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200368	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	134730	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104877	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	144199	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1113876	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1725846	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	337781	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80351	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2750	usd
CY2023Q3	us-gaap	Goodwill Goodwill	815500	usd
CY2022Q4	us-gaap	Goodwill Goodwill	815500	usd
CY2023Q3	us-gaap	Assets Assets	2349508	usd
CY2022Q4	us-gaap	Assets Assets	2939906	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1080473	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	738395	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	667413	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581802	usd
CY2023Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	136742	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3624414	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94105	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7258451	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1532813	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	251615	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2759961	usd
CY2023Q3	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	2839	usd
CY2022Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	6562	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7512905	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4582428	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39967598	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39967598	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38286598	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38286598	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	39968	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	38287	usd
CY2023Q3	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	200	usd
CY2022Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	1206	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21415082	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17343671	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26624036	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19032561	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5160678	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641289	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-2719	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1233	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5163397	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2349508	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2939906	usd
CY2023Q3	us-gaap	Revenues Revenues	453717	usd
CY2022Q3	us-gaap	Revenues Revenues	347159	usd
	us-gaap	Revenues Revenues	1047773	usd
	us-gaap	Revenues Revenues	1000945	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	79750	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	65020	usd
	us-gaap	Cost Of Revenue CostOfRevenue	218932	usd
	us-gaap	Cost Of Revenue CostOfRevenue	201873	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	373967	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	282139	usd
	us-gaap	Gross Profit GrossProfit	828841	usd
	us-gaap	Gross Profit GrossProfit	799072	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	682452	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1304512	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3283913	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	5191214	usd
CY2023Q3	us-gaap	Other General Expense OtherGeneralExpense	448836	usd
CY2022Q3	us-gaap	Other General Expense OtherGeneralExpense	715028	usd
	us-gaap	Other General Expense OtherGeneralExpense	2179288	usd
	us-gaap	Other General Expense OtherGeneralExpense	1757339	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	472544	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	517636	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1499633	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1750636	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	116437	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	114276	usd
	us-gaap	Professional Fees ProfessionalFees	319916	usd
	us-gaap	Professional Fees ProfessionalFees	472427	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1720269	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2651452	usd
	us-gaap	Operating Expenses OperatingExpenses	7282750	usd
	us-gaap	Operating Expenses OperatingExpenses	9171616	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1346302	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2369313	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6453909	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8372544	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	291318	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	291318	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	864454	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	840311	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	144499	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	104291	usd
	us-gaap	Interest Expense InterestExpense	363083	usd
	us-gaap	Interest Expense InterestExpense	223015	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-61111	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-157590	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-431817	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-720974	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1137027	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1485170	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1778119	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3090287	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7590936	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9857714	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2025	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	666616	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1778119	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3090287	usd
	us-gaap	Profit Loss ProfitLoss	-7592961	usd
	us-gaap	Profit Loss ProfitLoss	-10524330	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	593	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	77	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1486	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	70	usd
CY2023Q3	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-1777526	usd
CY2022Q3	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-3090210	usd
	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-7591475	usd
	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-10524260	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3090287	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7592961	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10524330	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.27
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967598	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40173220	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967517	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38425341	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	725000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-206755	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1211188	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2954465	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2454044	usd
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	136827	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-188795	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	994723	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2860377	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4267730	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	384690	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1067142	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5163397	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	467500	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2481510	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3644058	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4717436	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	375000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	111847	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	857835	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1405193	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3789985	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3677326	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	375000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	561100	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1304512	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3090287	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2827651	usd
	us-gaap	Profit Loss ProfitLoss	-7592961	usd
	us-gaap	Profit Loss ProfitLoss	-10524330	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12026	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200766	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3283913	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5191214	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	78510	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-157590	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	864454	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	840311	usd
	ohcs	Rightofuse Asset RightofuseAsset	-2591	usd
	ohcs	Rightofuse Asset RightofuseAsset	3324	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	666616	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	46046	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	128238	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6979	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	29853	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	16081	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	342078	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	104176	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	85611	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	207762	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3168858	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3032629	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-9000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	936330	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2203666	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	713622	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1403666	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	35431	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	29384	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	187277	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	779616	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	925000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	750000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	136827	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1935000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	1649800	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	3723	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	3686	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3318	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8263	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2430932	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2673051	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-550649	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	420038	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200368	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	680876	usd
	us-gaap	Interest Paid Net InterestPaidNet	200700	usd
	us-gaap	Interest Paid Net InterestPaidNet	99000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2025	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to: (1) advancing access to clinical trial research; and (2) improving and simplifying access to vaccines and pharmaceutical products. Currently the Company provides these services through its portfolio companies, Clinical Research Alliance, Inc. (CRA), and Worker’s Health Rx (d/b/a Vitality Rx).</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">Reclassification</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts included in prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s previously reported financial statements.</p>
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into a lease agreement commencing on July 1, 2023 through June 30, 2026, for 2,153 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200368	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	0	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	363153	usd
CY2022	ohcs	Accounts Receivable Percentage AccountsReceivablePercentage	0.10	pure
	ohcs	Accounts Receivable Percentage AccountsReceivablePercentage	0.10	pure
CY2023Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
	us-gaap	Operating Lease Payments OperatingLeasePayments	179	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q3	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
CY2022Q3	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	682452	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1304512	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3283913	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	5191214	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Advertising Expense AdvertisingExpense	17150	usd
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7586664	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8247289	shares
	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	ohcs	Rightofuseasset Office Lease RightofuseassetOfficeLease	485129	usd
CY2022Q4	ohcs	Rightofuseasset Office Lease RightofuseassetOfficeLease	456819	usd
CY2023Q3	ohcs	Rights Of Use Assets Equipment Lease RightsOfUseAssetsEquipmentLease	5611	usd
CY2022Q4	ohcs	Rights Of Use Assets Equipment Lease RightsOfUseAssetsEquipmentLease	2063	usd
CY2023Q3	ohcs	Accumulated Amortization Accumulated Amortization AccumulatedAmortizationAccumulatedAmortization	152959	usd
CY2022Q4	ohcs	Accumulated Amortization Accumulated Amortization AccumulatedAmortizationAccumulatedAmortization	119268	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	337781	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q3	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	344670	usd
CY2022Q4	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	348081	usd
CY2023Q3	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	1050	usd
CY2022Q4	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	2063	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94105	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	251615	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	28788	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	114163	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	117123	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	96406	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	49677	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	406157	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60437	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	345720	usd
	ohcs	Going Concerntext Block GoingConcerntextBlock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Going concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s consolidated financial statements are prepared using the GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At September 30, 2023 and December 31, 2022, the Company had $200,368 and $751,017 in cash and $6,144,575 in working capital deficit and $193,033 in working capital at September 30, 2023 and December 31, 2022, respectively. For the nine months ended September 30, 2023 and 2022, the Company had a net loss of $7,592,961 and $10,524,330 respectively. For the three months ended September 30, 2023 and 2022, the Company had a net loss of $1,778,119 and $3,090,287, respectively. Continued losses may adversely affect the liquidity of the Company in the future. At September 30, 2023 and December 31, 2022, the Company had accumulated deficits of $26,624,036 and $19,032,561, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of the matters described in the preceding paragraph, recoverability of a major portion of the recorded asset amounts shown in the accompanying consolidated balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has a total of $4.4 million in aggregate principal convertible notes outstanding, of which $2.2 million each matures on May 25, 2024 and June 7, 2024 respectively, and also has a demand note outstanding of $1,650,000 at September 30, 2023. In addition, the Company has operating costs and expenses at the present time for development of its business activities for which the Company will be required to raise additional capital over the next twelve months to meet its current administrative expenses and any debt as it may come due, and it may do so in connection with or in anticipation of possible acquisition transactions. This financing may take the form of additional sales of its equity securities and/or convertible notes. There is no assurance that additional financing will be available, if required, or on terms favorable to the Company.</p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200368	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q3	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	6144575	usd
CY2022Q4	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	193033	usd
	us-gaap	Profit Loss ProfitLoss	-7592961	usd
	us-gaap	Profit Loss ProfitLoss	-10524330	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1778119	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3090287	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26624036	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19032561	usd
CY2023Q3	ohcs	Convertible Notes Outstanding ConvertibleNotesOutstanding	1650000	usd
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.73	pure
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.51	pure
CY2021Q3	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	425000	usd
CY2021Q3	us-gaap	Shares Issued SharesIssued	425000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	1
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1.25
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	201333	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2023Q3	ohcs	Aggregate Principal Amount AggregatePrincipalAmount	200000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q3	us-gaap	Goodwill Goodwill	815500	usd
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	2000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	400000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	200000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022Q4	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3600000	usd
CY2022Q4	us-gaap	Beneficial Interest BeneficialInterest	100000	usd
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3500000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3627927	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	127927	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	96224	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	199098	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001892025
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	92126	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56696	usd
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	116022	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80592	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35671	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24396	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80351	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2023Q3	us-gaap	Depreciation Depreciation	7774	usd
	us-gaap	Depreciation Depreciation	11276	usd
CY2022Q3	us-gaap	Depreciation Depreciation	978	usd
	us-gaap	Depreciation Depreciation	1668	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	250	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2750	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	750	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	327440	usd
CY2022	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-183241	usd
CY2022	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	144199	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	78510	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-157590	usd
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	161269	usd
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	82759	usd
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	199725	usd
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	42135	usd
CY2023Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	136742	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0164	pure
	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	3318	usd
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.25	pure
	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	389111	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	76889	usd
	ohcs	Coupon Percentage CouponPercentage	0.12	pure
CY2022Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	362000	shares
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	218238	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1650000	usd
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2839	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5304	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3624414	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2759961	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3624414	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	144499	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	363083	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	104291	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	223015	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	291318	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	864454	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	291318	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	840311	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4341000	shares
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	1956000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	925000	usd
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1.25
	ohcs	Preferred Stock Voting Rightsshare PreferredStockVotingRightsshare	1.25
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2020Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	9998889	shares
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	250000	shares
CY2023Q3	us-gaap	Share Price SharePrice	1.25
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.4516	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0424	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5895000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6190000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.25
	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Term Options Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTermOptionsGranted	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1890000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.65
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10195000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M1D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1075000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.24
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y11M12D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3283913	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5191214	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7815007	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	70000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.27
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40173220	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense		usd
	us-gaap	Advertising Expense AdvertisingExpense		usd
CY2023Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent		usd
	ohcs	Gross Unrealized Loss GrossUnrealizedLoss		usd

Files In Submission

Name	View Source	Status
0001213900-23-084520-index-headers.html	Edgar Link	pending
0001213900-23-084520-index.html	Edgar Link	pending
0001213900-23-084520.txt	Edgar Link	pending
0001213900-23-084520-xbrl.zip	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-1_002.jpg	Edgar Link	pending
ex10-1_003.jpg	Edgar Link	pending
ex10-1_004.jpg	Edgar Link	pending
ex10-1_005.jpg	Edgar Link	pending
ex10-1_006.jpg	Edgar Link	pending
ex10-1_007.jpg	Edgar Link	pending
ex10-1_008.jpg	Edgar Link	pending
ex10-1_009.jpg	Edgar Link	pending
ex10-1_010.jpg	Edgar Link	pending
ex10-1_011.jpg	Edgar Link	pending
f10q0923ex10-1_optimushealth.htm	Edgar Link	pending
f10q0923ex31-1_optimushealth.htm	Edgar Link	pending
f10q0923ex31-2_optimushealth.htm	Edgar Link	pending
f10q0923ex32-1_optimushealth.htm	Edgar Link	pending
f10q0923ex32-2_optimushealth.htm	Edgar Link	pending
f10q0923_optimushealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
ohcs-20230930_pre.xml	Edgar Link	unprocessable
f10q0923_optimushealth_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ohcs-20230930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ohcs-20230930_lab.xml	Edgar Link	unprocessable
ohcs-20230930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q4 Form 10-Q Financial Statement

#000121390023084520 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q4 Form 10-Q Financial Statement

#000121390023084520 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs